1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Competitor Analysis: alpha1-Proteinase Inhibitors (alpha1-PI), alpha1-Antitrypsin (AAT) and Elastase Inhibitors

Competitor Analysis: alpha1-Proteinase Inhibitors (alpha1-PI), alpha1-Antitrypsin (AAT) and Elastase Inhibitors

The present Competitive Intelligence Report about alpha1-proteinase inhibitors (alpha1-PI), alpha1-antitrypsin (AAT) and elastase inhibitors provides a competitor evaluation in the field of human plasma-derived, recombinant, transgenic, synthetic and gene therapeutic approaches for treatment of lung emphysema caused by congenital deficiency and of other diseaes by synthetic elastase inhibitors or RNA approaches as of July 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.


Neutrophil elastase (NE) is a serine protease, expressed mainly by neutrophils, that is capable of degrading a variety of structural proteins of the extracellular matrix. Infiltration of activated neutrophils and excessive NE activity have been implicated in several lung diseases, including acute lung injury, cystic fibrosis, pulmonary fibrosis, COPD and bronchiectasis.



Endogenous human neutrophil elastase is predominantly neutralized by alpha-1 antitrypsin (AAT), also called alpha1-proteinase inhibitor (alpha1-PI). Congenital deficiency of AAT leads to emphysema which can be treated by substitution with therapeutic AAT. At present, alpha-1 antitrypsin products are human plasma-derived purified products. Recombinant AAT products are under development as well as gene therapy approaches to replace AAT. Downregulation of AAT is presently being evaluated as a therapeutic strategy to treat liver disease associated with Alpha-1 antitrypsin deficiency (AATD). AAT is currently also being evaluated as a treatment option for type 1 diabetes and graft-versus-host disease.



Neutrophil elastase also has attracted much interest as a target for inhibition to treat chronic obstructive pulmonary disease (COPD), asthma or bronchiectasis. Synthetic and recombinant elastase inhibitors have been identified and are in clinical and preclinical development.



The report includes a compilation of current active products and projects in research and development of human neutrophil elastase targeting small molecules, purified and recombinant proteins, peptides, RNA and DNA. In addition, the report lists company-specific R&D pipelines of alpha1-PI, antitrypsin and elastase inhibitors. Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: alpha1-Proteinase Inhibitors (alpha1-PI), alpha1-Antitrypsin (AAT) and Elastase Inhibitors
Competitor Analysis: alpha1-Proteinase Inhibitors (alpha1-PI), alpha1-Antitrypsin (AAT) and Elastase Inhibitors
Table of Contents

- Substitution with alpha1-Proteinase Inhibitors / alpha1-Antitrypsin
- Gene Therapy with alpha1-Proteinase Inhibitors / alpha1-Antitrypsin
- Downregulation of alpha1-Proteinase Inhibitors / alpha1-Antitrypsin
- Elastase Inhibitors
- Corporate alpha1-PI, Antitrypsin and Elastase Inhibitor RandD Pipelines

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.